PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Topical application of E. peplus sap showed complete clinical response rates at 1 month of 82% for basal cell carcinomas (BCC), 94% for intraepidermal carcinomas (IEC), and 75% for squamous cell carcinomas (SCC) [PMID:21375515].
The plant is a source for the drug ingenol mebutate (and the derivative ingenol-3-angelate/Picato) used to treat this precancerous skin condition [PMID:36757383, PMID:23907534, PMID:40671640].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 30058659 (2018) — Hot off the Press. · Natural product reports
- 2.PMID: 40671640 (2025) — Identification of BAHD-acyltransferase enzymes involved in ingenane diterpenoid biosynthesis. · The New phytologist
- 3.PMID: 32290691 (2021) — Three new diterpenoids from Euphorbia peplus. · Natural product research
- 4.PMID: 36757383 (2023) — Chromosome-level Genome Assembly of Euphorbia peplus, a Model System for Plant Latex, Reveals that Relative Lack of Ty3 Transposons Contributed to Its Small Genome Size. · Genome biology and evolution
- 5.PMID: 40454263 (2025) — The genome sequence of petty spurge, Euphorbia peplus L. (Euphorbiaceae).